Moderna plunges on downgrade amid vaccine headwinds
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Deutsche Bank Upgrades Moderna (MRNA) to Hold, 'a more troublesome Winter’s Tale, but up to Hold'
August 6, 2024 4:18 PM EDTDeutsche Bank analyst Emmanuel Papadakis upgraded Moderna (NASDAQ: MRNA) from Sell to Hold with a price target of $80.00 (from $85.00).
The analyst comments "We update after Q2s difficult print (Moderna: Q2 first take. Set to be pursued by many bears?*: winter reckoning arrives early (01/08/24)), which delivered the triple-blow of downgraded revenue, reduced gross margin and maintained... More
